# US 2017/0240588 A1 · Amphiphilic compounds with neuroprotective properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0240588 A1
- Document ID: US20170240588A1
- Status: Published application
- Kind: A1
- Application number: 15/506,318
- Filed: 2015-08-25
- Published: 2017-08-24
- Earliest claimed: 2014-08-26
- Assignees: Ustav Organicke Chemie A Biochemie Av Cr, V.V.I.; Fyziologicky Ustav Av Cr, V.V.I.
- Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, v.v.i.; FYZIOLOGICKY USTAV AV CR, v.v.i.
- Inventors: Eva KUDOVA; Hana CHODOUNSKA; Vojtech KAPRAS; Ladislav VYKLICKY; Karel VALES; Ullrich JAHN
- Web page: https://patentgrep.com/patent/US20170240588A1

## CPC

- C07J 43/003: {not condensed}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 23/00: Anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 35/00: Antineoplastic agents
- C07C 59/80: containing rings other than six-membered aromatic rings
- C07C 305/20: having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07D 209/36: in position 3, e.g. adrenochrome
- C07D 213/18: Salts thereof
- C07D 317/72: spiro-condensed with carbocyclic rings
- C07J 1/0007: {not substituted in position 17}
- C07J 1/0011: {substituted in position 17 by a keto group}
- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J 9/005: {containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton}
- C07J 13/007: {with double bond in position 17 (20)}
- C07J 31/006: {not covered by C07J31/003}
- C07J 41/0005: {the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton}
- C07J 41/0033: {not covered by C07J41/0005}
- C07J 41/0038: {with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group}
- C07J 53/001: {spiro-linked}
- C07J 63/008: {Expansion of ring D by one atom, e.g. D homo steroids}
- C07J 71/0005: {Oxygen-containing hetero ring}
- C07C 2603/26: Phenanthrenes; Hydrogenated phenanthrenes
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use in methods of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing compound.

## Claims

### Claim 1

An amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I,
wherein
R1 is selected from the group comprising (—OSO3pyH), (—OSO3Na), (—OSO3H), NaOOC—R6—C(R7)—R8—, HOOC—R6—C(R7)—R8—, HOOC—Cu (R7)—R8—, or R9—R10—C(R11)—R12—, where
R6 represents straight or branched C1 to C6 alkylene or C2 to C6 alkenylene chain, unsubstituted or substituted with one or more halogen atoms or amino group or amino group protected by protecting groups, preferably by tert-butylcarbonyl,
or R6 means trivalent —CH(CH2−—)2 alkylene that forms with the carbon carrying R7 and with R8 being nitrogen a five-membered ring ;
R7 represents atom of oxygen, nitrogen or sulphur bound by double bond, or two atoms of hydrogen,
R8 represents an at least divalent atom, preferably nitrogen, oxygen or carbon,
R9 represents a cationic group selected from guanidinyl derivatives of formula (a),
and quaternary ammonium groups of formula (b)
wherein R13 to R2° are selected from hydrogen atoms, linear or branched C1 to C6 alkyl, linear or branched C2 to C6 alkenyl,
R10 represents straight or branched C1 to C6 alkylene or C2 to C6 alkenylene, wherein the alkylene and alkenylene are unsubstituted or substituted by 1 to 10 halogen atoms or by amino group which is primary or substituted by linear or branched C1 to C4 alkyl;
R11 represents atom of oxygen, nitrogen or sulphur bound by double bond, or two atoms of hydrogen, and
R12 is selected from the group comprising oxygen, nitrogen and carbon atoms, and when R12 is carbon or nitrogen, its further valences are occupied by hydrogen or hydrogens, while any of hydrogen can be replaced by C1 to C4 alkyl or C2 to C4 alkenyl;
R2 represents hydrogen atom or methyl;
R3 represents a) hydrogen atom, and then
i) R4 and R5 are hydrogen atoms, or
ii) one of R4 and R5 represents hydrogen atom and the other one represents a straight or branched C1 to C6 alkyl or C2 to C6 alkenyl chain, optionally substituted by 1 to 13 halogen atoms in case of alkyl and by 1 to 9 halogen atoms in case of alkenyl, or by atom of oxygen or sulphur bound by a double bond, while one of the methylene groups in the chain is optionally replaced by oxygen or sulphur atom; or
b) straight or branched C1 to C6 alkyl or C2 to C6 alkenyl, optionally substituted by 1 to 13 halogen atoms in case of alkyl or by 1 to 9 halogen atoms in case of alkenyl, or by atom of oxygen or sulphur bound by a double bond, while one of the methylene groups in the chain is optionally replaced by oxygen or sulphur atom, and then R4 and R5 are hydrogen atoms, or
c) C5 or C6 alicyclic or aromatic substituent, while carbon atoms can be functionalized by 1 to 8 atoms of halogen in case of five-membered alicyclic ring, or 1 to 10 halogen atoms in case of six-membered alicyclic ring or by 1 to 4 halogen atoms in case of five-membered aromatic ring or 1 to 5 halogen atoms in case of six-membered aromatic ring; and then
i) R5 is selected from the group comprising hydrogen atom, linear or branched C1 to C6 alkyl, linear or branched C2 to C6 alkenyl, wherein alkyl or alkenyl is optionally substituted by 1 to 13 halogen atoms in case of alkyl and by 1 to 9 halogen atoms in case of alkenyl, or by double bond bound atom of oxygen or sulphur, while one of the methylene groups in the chain is optionally replaced by oxygen or sulphur atom, or
ii) R4 and R5 represent alkylene or alkenylene substituent —(CHm)n—, where n=3-4, m=1-2, forming with the parent carbon atoms of the skeleton at position 7 and 8 saturated or unsaturated 5- or 6-membered cycle, wherein the hydrogen atoms of the alkenylene substituent are optionally substituted at least by one halogen atom or linear or branched C1 to C4 alkyl or C2 to C4 alkenyl chain, wherein optionally one methylene group of the alkylene substituent forming the ring is replaced by carbonyl group and the carbon atom at the adjoining position is optionally substituted by another methylene group, or one methylene group of the alkylene substituent forming the ring is optionally replaced by oxygen or sulphur atom, while the sulphur atom is optionally functionalized by oxygen atom; or the hydrogens of one methylene group of alkylen substituent are optionally replaced by —O—CH2—, thereby forming oxirane ring,
d) substituent —CH2—O—CH(CH3)—, then together with the first carbon of the alkylene group formed by R4 and R5, whereinR4 and R5 represent alkylene substituent —(CH2)3—, forms a saturated and methylated heretocycle;
and enantiomers of compounds of general formula I, with the proviso that compounds wherein R1 represents HO2C—R6CR7—R8—, R6 is —(CH2)2—, R7 is oxygen atom bound by double bond and R8 is oxygen atom, while R2 and R3 are methyl groups, R4 and R5 together form group —(CH2)3— forming with parent carbon atoms of tetradecahydrophenanthrene skeleton at position 7 and 8 a saturated five-membered ring; with absolute configuration 3R,5S,8S,9S,10S,13S,14S are excluded from formula I.

### Claim 2 (depends on 1)

The amphiphilic compound of general formula I according to claim 1, selected from:
pyridinium (2R,4aS,4bS,8aR,10aR)-4a-methyltetradecahydrophenanthren-2-yl 2-sulfate (8), pyridinium (2R,4aS,4bS,7 S,8S,8 aS,10aR)-7-(methoxymethyl)-4a,7,8-trimethyltetradecahydrophenanthren-2-yl 2-sulfate (18),
4-(((2R,4aS,4bS,7S,8aS,10aR)-7 -(methoxymethyl)-4a,7,8-trimethyltetradecahydrophenanthren-2-yl)oxy)-4-oxobutanoic acid (19),
pyridinium (2R,4aS,7S, 8S,10aR)-7-(methoxycarbonyl)-4a,7 ,8-trimethyltetradecahydrophenanthren-2-yl 2-sulfate (22),
4-(((2R,4aS,4bS,7R,8aS,10aR)-4a,7-dimethyltetradecahydrophenanthren-2-yl)oxy)-4-oxobutanoic acid (34),
pyridinium (2R,4aS,4bS,7R,8aS,10aR)-4a,7-dimethyltetradecahydrophenanthren-2-yl 2-sulfate (35), methyl (2S,4aS,4bS,7R,8aR,10aS)-2,4b-dimethyl-7-(sulfooxy)tetradecahydrophenanthren-2-carboxylate (40),
pyridinium (3R,5R,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (49),
2-(((3R,5R,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxoethanoic acid (50),
2-(((3R,5R,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxopropanoic acid (51),
2-(((3R,5R,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)-2-oxoacetic acid (59),
((3R,5R,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]fenanthren-3-yl)amino)-3-oxopropanoic acid (61),
4-(((3R,5R,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-N,N,N-trimethyl-4-oxobutan-l-amonium chloride (62),
4-(((3R,5R,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-4-oxobutanoic acid (64),
3-(((3R,5R,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3-oxopropanoic acid (65),
3-(((3R,5R,8R,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3-oxopropanoic acid (67),
4-(((3R,5R,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-4-oxobutanoic acid (68),
4-(((3R,5R,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-4-oxopentanoic acid (69),
2-((3R,5R,8R,9S,10S,13S,14S)-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopentalalphenanthren-3-yl)acetic acid (74),
2-(((3R,5R,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-N,N,N-trimethyl-2-oxoethan-1-ammonium chloride (76),
3-(((3R,5R,8R,9S,10S,13S,14S,Z)-17-ethylidene-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3-oxopropanoic acid (83),
5-(((3R,5R,8R,9S,10S,13S,14S,Z)-17-ethylidene-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-5-oxopentanoic acid (85),
3-(((3R,5R,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-17-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3-oxopropanoic acid (88),
pyridinium (3R,5R,8R,9S,10S,13S,14S,17S)-17-iodo-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (93),
pyridinium (3R,5R,8R,9S,10S,13S,14S)-17,17-difluoro-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (95),
pyridinium (3R,5R, 8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospirolcyclopenta-[a]phenanthren-17,2′-oxiranel-3-yl 3-sulfate (97),
pyridinium (2R,4aS,4bS,6aS,10bS,6aS,12aR)-4a,6a-dimethyloctadecahydrochrysen-2-yl 2-sulfate (101),
(4S)-4-amino-5-(((2R,4aS,4bS,6aS,10bS,12aR)-4a,6a-dimethyloctadecahydrochrysen-2-yl)oxy)-5-oxopentanoic acid (106),
pyridinium (3R,5R,8S,9S,10S,13R,14S)-10,13-dimethyl-16-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (114),
pyridinium (3R,5R,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (116),
pyridinium (3R,5R,8S,9S,10S,13R,14S,17S)-10,13,17-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (117),
pyridinium (3R,5R,8S,9S,10S,13S,14R,17R)-10,17-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (118),
pyridinium (3R,5R,8S,9S,10S,13R,14R,17S)-10,17-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (119),
pyridinium (3R,5R,8S,9S,10S,13R,14S,17S)-17-ethyl-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (120),
pyridinium (3R,5R,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-17-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (121),
pyridinium (3R,5R,8R,9S,10S,13R,14S,17R)-17-isopropyl-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (122),
pyridinium (3R,5R,8R,9S,10S,13R,14S,17R)-174(R)-sec-butyl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (123),
pyridinium (3S,3aS,5bR,7aR,9R,11aS,11bS,13aR)-3,11a-dimethylhexadecahydro-1H,3H-naphthol[2′,1′:4,5]indeno[1,7a-c]furan-9-yl 9-sulfate (124),
pyridinium (3R,5R,8R,9R,10S,13S,14S)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-sulfate (126),
pyridinium (3R,5S,8R,9R,10S,13S,14S)-10,13-dimethylhexadecahydro-1H- cyclopenta[a]phenanthren-3-yl 3-sulfate (127),
pyridinium (2S,4aR,4bR,8aS,10aS)-4a-methyltetradecahydrophenanthren-2-yl 2-sulfate (128),
(4S)-4-amino-5-(((3R,5R,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-5-oxopentanoic acid (130),
1-((3R,5R,8S,9S,10S,13S,14S)-10,13-Dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-5-oxopyrrolidine-3-carboxylic acid (131), mixture of isomers sodium 2-oxo-2-(((3R,5R,8S,9S,10S,13R,14S,17S)-10,13,17-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)acetate (138),
3-oxo-3-(((3R,5R,8S,9S,10S,13R,14S,17S)-10,13,17-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)propanoic acid (140),
sodium 2-(((3R,5R,8R,9S,10S,13R,14S)-174(R)-sec-butyl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)-2-oxoacetate (148),
3-(((3R,5R,8R,9S,10S,13R,14S)-17-((R)-sec-butyl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)-3-oxopropanoic acid (149),
2-(((3R,5R,8R,9S,10S,13S,14S,Z)-17-ethylidene-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)-2-oxoacetic acid (154),
3-(((3R,5R,8R,9S,10S,13S,14S,Z)-17-ethylidene-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)amino)-3-oxopropanoic acid (155).

### Claim 3 (depends on 1)

The amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I according to claim 1 for use as a medicament.

### Claim 4 (depends on 1)

The amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I according to claim 1 for use in a method of treatment of neuropsychiatric disorders associated with imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.

### Claim 5 (depends on 1)

A pharmaceutical composition for human or veterinary use, characterized in that it comprises as active ingredient at least one amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I according to claim 1.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, for use in a method of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.

### Claim 7 (depends on 1)

Use of the amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I according to claim 1, for the manufacture of veterinary and human pharmaceutical composition for treating neuropsychiatric disorders associated with imbalance of glutamatergic neurotransmitter system, such as ischemic damage to the central nervous system, neurodegenerative changes and disorders of the central nervous system, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.

### Claim 8 (depends on 1)

Use of an amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I according to claim 1, for manufacturing standards of neuroprotective agents, antidepressants, antianxiety, mood stabilizers, hypnotives, sedatives, analgesics, anesthetics, antipsychotics, neuroleptics and procognitives or analytical standards used in experimental research and analytical chemistry.

### Claim 9 (depends on 1)

Use of an amphiphilic compound with tetradecahydrophenanthrene skeleton of general formula I according to claim 1, as food additives or active ingredients of cosmetic preparations intended for improving the response of the individual parts of the organism to increased stress, in particular to increased oxidative stress, nutritional stress and stress caused by free radicals, or to aging.
